Ana I Flores

Ana I. Flores is the Principal Investigator of the Regenerative Medicine Group included in the Cross-sectional area, one of the nine priority research areas of the Instituto de Investigacion Hospital 12 de Octubre (imas12) of Madrid, Spain.

She obtained her Degree in Pharmacy with high honour at the University of Salamanca, and her Ph.D. in Chemical Sciences at the Department of Molecular Biology, Center of Molecular Biology Severo Ochoa (CBMSO) at the University Autonoma of Madrid in Spain. Dr. Flores Thesis Dissertation was awarded with the degree summa cum laude and received the Ph.D. Award from the University Autonoma de Madrid.

She completed a postdoctoral research in the United States at the Department of Physiology and Biophysics, Case Western Reserve University and at Department of Neurosciences, Cleveland Clinic Foundation, both institutions in Cleveland, Ohio. During her postdoctoral tuition at the Cleveland Clinic, she was awarded with a Post-doctoral Fellowship Grant and with the Dale McFarlin Travel Award, both prices from The National Multiple Sclerosis Society.

Following her postdoctoral training, she joined the Hospital 12 de Octubre in Madrid with a research contract from the National Health System del Instituto de Salud Carlos III to start a new research area focused in the isolation, characterization and preclinical/translational studies about mesenchymal stem cells obtained from the human placenta. The work about “Mesenchymal Stem Cells from Human Placenta” was recognized as “One of the best Ideas in the Health System from the Year 2010” in the area Research and Farmacology.

She has obtained projects as principal investigator, both from public entities and private, and an integrated project of excellence of the accredited IIS of the Institute of Health Carlos III, and a project of the R&D Activities Program between research groups of the Community of Madrid in Technologies 2013, co-financed with structural funds.

She participates as evaluator of projects of different National and International agencies such as the National Evaluation and Prospective Agency (ANEP), Unified System of Evaluation of Research, Development and Innovation (SUVIDI) of the Ministry of Economy and Competitiveness, Agency for the Quality of the University System of Castilla y León (ACSUCYL), Andalusian Public Progress and Health Foundation, RIS3 Euskadi and European Research Council (ERC).

She has been a member for 3 years of a Network of Spanish and European excellence for prevention and local treatment of osteoporotic fractures, until it has been completed. She is member of the Biobank Scientific Committee at the Research Institute Hospital 12 de Octubre (imas 12). She is also a member of the First Intervention Team for the Research Center of the October 12 Hospital. She is a member of the Board of Directors of the Spanish Society of Regenerative Medicine and Cellular Therapy (SEMERETEC).

She has participated in the Healthstart madri+d 2020 Program with the project "Stem cell method for incontinence" which was one of the five projects selected as one of the most innovative initiatives in the health sector in the region and endowed with a prize of 10,000 euros in services aimed at the maturation and development of projects. Heatlhstart is the madri+d Foundation for Knowledge program to promote the creation of technological start-ups in the health sector of the Community of Madrid. Heatlhstart is a training program in technological entrepreneurship from health research environments, completed with other tailored activities and services. She has a technological platform where she develops Regenerative Medicine treatments that use stem cells to regenerate damaged organs or tissues https://www.celmaes.com/